Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma has limited treatment options, but there has been extensive growth recently with cabozantinib, regorafenib, lenvatinib, nivolumab, atezolizumab, and bevacizumab, which are some of the treatments that have received FDA approval just over the last three years. Because...
Main Authors: | Robin Park, Fariha Eshrat, Mohammed Al-Jumayli, Azhar Saeed, Anwaar Saeed |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/8/3/447 |
Similar Items
-
Immunotherapies for advanced hepatocellular carcinoma
by: Li-Yang Sun, et al.
Published: (2023-03-01) -
A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma
by: Alireza Tojjari, et al.
Published: (2023-08-01) -
The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions
by: Jianbo Ning, et al.
Published: (2024-10-01) -
The Immunology of Hepatocellular Carcinoma
by: Gbemisola Lawal, et al.
Published: (2021-10-01) -
Immune checkpoint inhibition (ICI) in current systemic therapies for hepatocellular carcinoma (HCC)
by: F. van Bömmel, et al.
Published: (2023-10-01)